BST:OCY

Stock Analysis Report

Executive Summary

Oncimmune Holdings plc develops and commercializes products to diagnose cancer in the United Kingdom, North America, Europe, and internationally.


Snowflake Analysis

High growth potential with mediocre balance sheet.

Share Price & News

How has Oncimmune Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OCY's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.6%

OCY

8.1%

DE Biotechs

7.2%

DE Market


1 Year Return

-43.4%

OCY

-5.4%

DE Biotechs

-17.5%

DE Market

Return vs Industry: OCY underperformed the German Biotechs industry which returned -5.4% over the past year.

Return vs Market: OCY underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

OCYIndustryMarket
7 Day4.6%8.1%7.2%
30 Day-13.4%-11.8%-22.3%
90 Day20.9%-22.7%-26.1%
1 Year-43.4%-43.4%-5.2%-5.4%-14.9%-17.5%
3 Year-60.9%-60.9%17.6%16.3%-18.7%-25.7%
5 Yearn/a-5.1%-7.5%-17.8%-29.1%

Price Volatility Vs. Market

How volatile is Oncimmune Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Oncimmune Holdings undervalued compared to its fair value and its price relative to the market?

13.54x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OCY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OCY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OCY is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: OCY is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OCY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OCY is overvalued based on its PB Ratio (13.5x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Oncimmune Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

48.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OCY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: OCY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OCY's is expected to become profitable in the next 3 years.

Revenue vs Market: OCY's revenue (39.5% per year) is forecast to grow faster than the German market (4.2% per year).

High Growth Revenue: OCY's revenue (39.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OCY is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Oncimmune Holdings performed over the past 5 years?

-9.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OCY is currently unprofitable.

Growing Profit Margin: OCY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OCY is unprofitable, and losses have increased over the past 5 years at a rate of -9.6% per year.

Accelerating Growth: Unable to compare OCY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OCY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: OCY has a negative Return on Equity (-438.23%), as it is currently unprofitable.


Next Steps

Financial Health

How is Oncimmune Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: OCY's short term assets (£8.7M) exceed its short term liabilities (£2.2M).

Long Term Liabilities: OCY's short term assets (£8.7M) exceed its long term liabilities (£8.3M).


Debt to Equity History and Analysis

Debt Level: OCY's debt to equity ratio (331.9%) is considered high.

Reducing Debt: OCY had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: OCY has a low level of unsold assets or inventory.

Debt Coverage by Assets: OCY's debt is covered by short term assets (assets are 1.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OCY has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OCY has less than a year of cash runway if free cash flow continues to reduce at historical rates of -24.2% each year


Next Steps

Dividend

What is Oncimmune Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OCY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OCY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OCY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OCY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OCY's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Adam Hill (39yo)

1.5s

Tenure

UK£258,000

Compensation

Dr. Adam Mark Hill, MB, PhD, has been the Chief Executive Officer at Oncimmune Holdings Plc since September 2018. Dr. Mark also served as Director at Oncimmune Holdings Plc. He served as Chief Medical Offi ...


CEO Compensation Analysis

Compensation vs Market: Adam's total compensation ($USD320.24K) is about average for companies of similar size in the German market ($USD432.27K).

Compensation vs Earnings: Adam's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Adam Hill
CEO & Director1.5yrsUK£258.00kno data
Andrew Millet
Executive1.25yrsUK£215.36kno data
Matthew Hall
Group Chief Financial Officer1.25yrsno datano data
Tariq Sethi
Chief Scientific Officer0.42yrno datano data
Cléa Rosenfeld
Head of Investor Relations0.67yrno datano data
Andrew Stewart
General Counsel & Company Secretary1.25yrsno datano data
James Jett
Chief Medical Officer of US4.17yrsno datano data
Maarten Brusse
Chief Commercial Officer of Asia3.5yrsno datano data
Shane Smith
Senior Vice President of Market Access & Reimbursement Oncimmune (Usa)2.92yrsno datano data
Matthew Luttrell
Chief Commercial Officer0.42yrno datano data

1.3yrs

Average Tenure

Experienced Management: OCY's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Adam Hill
CEO & Director1.5yrsUK£258.00kno data
Julian Hirst
Independent Non-Executive Director3.75yrsUK£36.00kno data
Timothy Bunting
Non-Executive Directorno datano data4.44% £1.5m
Andrew Unitt
Independent Non Executive Director6.17yrsUK£18.00kno data
Geoffrey Hamilton-Fairley
Non-Executive Vice Chairman1.5yrsUK£146.00k5.12% £1.8m
Annalisa Jenkins
Senior Independent Non-Executive Directorno dataUK£36.00kno data
Richard Sharp
Non Executive Director4.42yrsno datano data
Meinhard Schmidt
Non-Executive Chairman4.5yrsUK£75.00kno data
Carsten Schroeder
Independent Non-Executive Director3.42yrsUK£41.00k0.014% £4.9k
Cheung To
Non-Executive Director1.5yrsno datano data

3.8yrs

Average Tenure

54.5yo

Average Age

Experienced Board: OCY's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: OCY insiders have bought and sold the same number of shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.


Top Shareholders

Company Information

Oncimmune Holdings plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oncimmune Holdings plc
  • Ticker: OCY
  • Exchange: BST
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£30.993m
  • Listing Market Cap: UK£34.696m
  • Shares outstanding: 63.25m
  • Website: https://www.oncimmune.com

Number of Employees


Location

  • Oncimmune Holdings plc
  • D6 Building
  • 1 Thane Road
  • Nottingham
  • Nottinghamshire
  • NG90 6BH
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ONCAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMay 2016
OCYBST (Boerse-Stuttgart)YesOrdinary SharesDEEURMay 2016

Biography

Oncimmune Holdings plc develops and commercializes products to diagnose cancer in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops EarlyCDT-Liver, a blood test for the early detection of hepatocellular carcinoma in high-risk patients with liver lesions of all sizes; SeroTag, a platform that is used to discover and validate biomarkers and develop precision diagnostic tools from minimally-invasive liquid biopsies; and NavigAID for autoimmune diseases. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/27 23:41
End of Day Share Price2020/03/27 00:00
Earnings2019/11/30
Annual Earnings2019/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.